Ascletis Pharma
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Building D 198 Qidi Rd 12TH Fl, Hipark, ...Phone Number
+86 57185389730Website
www.ascletis.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ascletis Pharma
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including small molecules and peptides for chronic weight management. Ascletis aims to address global unmet medical needs and is listed on the Hong Kong Stock Exchange. Their target clients include healthcare providers and patients seeking effective treatments for metabolic and immune diseases.Explore more
Ascletis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascletis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ascletis Pharma has new funding data
Check if Ascletis Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ascletis Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ascletis Pharma
Earning: See what the market has to say on Ascletis Pharma recently announced quarterly report
Check out if Ascletis Pharma is spiking on competitors!
Ascletis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Ascletis Pharma launches new products
Recommended Actions
Reach out to Masked Content who joined Ascletis Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ascletis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ascletis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ascletis Pharma.
Ascletis Pharma financials insights
Gather financial insights about Ascletis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$100M
2015
Private Equity
$35M
Unspecified
$20M
2017
Series B
$100M
Ascletis Pharma Tech Stack
A closer look at the technologies used by Ascletis Pharma
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Executive Move
Board of Directors
Executive Move
Board of Directors
Promotion
Executive Move
John Gargiulo has been promoted to the role of Chief Business Officer.
New Hire
Executive Move
Ascletis Pharma News & Media
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg)...Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly SQ injection which targets amylin receptor. -Investigational New Drug (IND) Applications for both ASC36 injection and ASC36_35FDC were recently cleared by the U.S. Food and Drug Administration (FDA). HOAscletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in non-human primates announced for first-in-class...Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascletis Pharma
Sign Up For FreeTo access detailed company insights
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including... Read More
